Review summary
Teaching objective: Evaluation of recurrent transient episodes of collapse in a 54-year-old man, separating seizure from convulsive syncope and transient ischemic attack (history from a witness, orthostatic vital signs, ECG and ambulatory cardiac monitoring under the ACC/AHA/HRS 2017 syncope guideline; EEG and MRI with diffusion-weighted and epilepsy-protocol sequences; CT angiography of the head and neck and echocardiography), and the diagnosis of late-onset focal epilepsy with a structural vascular cause from a clinically unrecognized cortical infarct, classified by the ILAE 2017 seizure and epilepsy classifications and the ILAE 2014 practical definition. Management follows the AAN/AES 2015 first-seizure guideline (recurrence risk and the case for treatment), the AAN/AES 2018 guideline on newer antiseizure medicines (levetiracetam, with mood monitoring), and the AHA/ASA 2021 secondary stroke prevention guideline with the CMID stroke, hypertension, and hyperlipidemia monographs (aspirin, high-intensity atorvastatin to an LDL below 70 mg/dL, blood pressure below 130/80 mmHg, 30-day rhythm monitoring, depression and cognitive screening), together with seizure safety and driving restrictions, an intercurrent respiratory infection, and an adult preventive visit. The historical dispute between epilepsy and cerebrovascular disease stays unresolved (R); the modern episode makes no claim about what he had.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| 12 or 13 July 100 BC | Born Gaius Julius Caesar in Rome. | CLM-0001 |
| 84 BC, in his sixteenth year | His father dies suddenly in the morning, with no cause recorded. | CLM-0002, CLM-0003 |
| about 82 to 81 BC | In hiding from Sulla's agents while ill with a quartan fever. | CLM-0004 |
| 54 BC | His daughter Julia dies in childbirth. | CLM-0010 |
| date not recorded | Plutarch places his first epileptic fit at Corduba in Spain; Suetonius records fainting fits and nightmares towards the end of his life and two attacks of the falling sickness on campaign. | CLM-0005, CLM-0006 |
| 6 April 46 BC in the old Roman calendar (about 7 February 46 BC, Julian) | Battle of Thapsus; by one account his usual sickness seized him and he was carried to a tower. | CLM-0007 |
| July to early November 46 BC (old Roman calendar) | In Rome: four triumphs within a month; the long year of 445 days that realigned the calendar. | CLM-0011, CLM-0012 |
| 1 January 45 BC | The Julian calendar takes effect. | CLM-0012 |
| late 45 or early 44 BC | Does not rise for the senators and blames his illness; Plutarch doubts the excuse. | CLM-0008 |
| 15 March 44 BC (the Ides of March) | Assassinated at a meeting of the Senate in Rome. | CLM-0016 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Gaius Julius Caesar was born on 12 or 13 July 100 BC in the Subura district of Rome, into the patrician family of the Julii. The day and year rest on later ancient testimony; the date is in the pre-Julian Roman calendar. |
probable | Julius Caesar supports |
| D | Suetonius writes that he lost his father 'in the course of his sixteenth year'. | confirmed | Suetonius, The Lives of the Caesars: The Life of Julius Caesar (translated by J. C. Rolfe, Loeb Classical Library, 1913) supports Julius Caesar context |
| D | Pliny the Elder records that two men of the family, one of them his father, a former praetor, 'died without any apparent cause, in the morning, while putting on their shoes'. The cause of death is not recorded. Modern writers have read these sudden deaths as cardiovascular deaths or as sudden death in epilepsy; both readings are retrospective. |
probable | Pliny the Elder, The Natural History, Book 7, chapter 54 (translated by J. Bostock and H. T. Riley, 1855) supports Julius Caesar context Dictator Perpetuus: Julius Caesar--did he have seizures? If so, what was the etiology? (Hughes JR. Epilepsy Behav 2004;5:756-64) context Julius Caesar may have suffered mini-strokes, study finds (AFP report) context |
| D | As a young man, in hiding from Sulla's agents, he was 'suffering from a severe attack of quartan ague' and changed his hiding place almost every night. A fever recurring every fourth day; modern readers usually take quartan fever to be malaria. Not used as a modern diagnosis. |
probable | Suetonius, The Lives of the Caesars: The Life of Julius Caesar (translated by J. C. Rolfe, Loeb Classical Library, 1913) supports Suetonius, De Vita Caesarum: Divus Julius (Latin text) supports |
| D | Plutarch describes him as 'of a spare habit', with 'a soft and white skin', and says he 'suffered from distemper in the head, and was subject to epileptic fits', the first of which attacked him at Corduba; he made 'his military service a cure for his feeble health'. Plutarch wrote about a century and a half later. The Corduba attack is not dated. |
confirmed | Plutarch, Parallel Lives: The Life of Caesar (Loeb Classical Library, volume VII, 1919) supports |
| D | Suetonius says he was tall, of sound health, 'except that towards the end he was subject to sudden fainting fits and to nightmare as well', and that he was 'twice attacked by the falling sickness' (comitialis morbus) during his campaigns. The ancient term comitialis morbus is usually translated as epilepsy, but it covered any falling attack; the description fits several modern diagnoses. |
confirmed | Suetonius, The Lives of the Caesars: The Life of Julius Caesar (translated by J. C. Rolfe, Loeb Classical Library, 1913) supports Suetonius, De Vita Caesarum: Divus Julius (Latin text) supports |
| D | Plutarch gives a second account of the battle of Thapsus in Africa in 46 BC, in which 'his usual sickness laid hold of him' as he was drawing up his army, and, sensing it coming, he was carried to a nearby tower and stayed there during the battle. Plutarch reports this only as what others say; it may not have happened. The battle is dated 6 April 46 BC in the pre-Julian Roman calendar, about 7 February 46 BC in Julian terms. |
possible | Plutarch, Parallel Lives: The Life of Caesar (Loeb Classical Library, volume VII, 1919) supports Battle of Thapsus context |
| D | When he did not rise to receive the senators, he afterwards 'made his disease an excuse', saying that the senses of those so afflicted do not stay steady when they address a standing crowd, with giddiness and insensibility; Plutarch says the excuse was not true. An episode late in his life, after the period of the modern episode. Plutarch himself doubts the illness was the reason. |
probable | Plutarch, Parallel Lives: The Life of Caesar (Loeb Classical Library, volume VII, 1919) supports Has the diagnosis of a stroke been overlooked in the symptoms of Julius Caesar? (Galassi FM, Ashrafian H. Neurol Sci 2015;36:1521-2) context |
| D | He drank very little wine: 'not even his enemies denied' it. | confirmed | Suetonius, The Lives of the Caesars: The Life of Julius Caesar (translated by J. C. Rolfe, Loeb Classical Library, 1913) supports |
| D | His only daughter, Julia, died in childbirth in 54 BC. | probable | Julius Caesar supports |
| D | After the African campaign he returned to Rome in July 46 BC, celebrated four triumphs within a single month, and left Rome for Further Spain early in November 46 BC. Places him in Rome for the whole true frame of the modern episode. |
confirmed | Caesar, The Spanish War: Introduction (Loeb Classical Library, 1955) supports Suetonius, The Lives of the Caesars: The Life of Julius Caesar (translated by J. C. Rolfe, Loeb Classical Library, 1913) supports Julius Caesar supports |
| D | He reformed the Roman calendar, which had drifted so far that the harvest festivals no longer came in summer, to a year of 365 days with a day added every fourth year; to realign it he lengthened 46 BC to 445 days, and the new calendar took effect on 1 January 45 BC. Dates in 46 BC and earlier are in the old Roman calendar and cannot be converted exactly; early Julian dates before about 8 BC are also uncertain by a day or so because leap years were at first inserted every third year. |
confirmed | Suetonius, The Lives of the Caesars: The Life of Julius Caesar (translated by J. C. Rolfe, Loeb Classical Library, 1913) supports Julian calendar supports |
| R | Retrospective readings take the attacks as epilepsy: one review counts four attacks that were probably complex partial (focal impaired-awareness) seizures and suggests an inherited cause; another treats them as late-onset epilepsy beginning at about 54 and proposes neurocysticercosis. Retrospective diagnoses from ancient texts; neither can be tested. |
disputed | Dictator Perpetuus: Julius Caesar--did he have seizures? If so, what was the etiology? (Hughes JR. Epilepsy Behav 2004;5:756-64) supports Julius Caesar's late onset epilepsy: a case of historic proportions (McLachlan RS. Can J Neurol Sci 2010;37:557-61) supports Was Julius Caesar's epilepsy due to neurocysticercosis? (Bruschi F. Trends Parasitol 2011;27:373-4) context |
| R | Galassi and Ashrafian (2015) argued that his symptoms (headache, vertigo, falls, limb weakness, the collapse at Thapsus, and the giddiness at the Senate) fit cerebrovascular disease with transient ischemic attacks better than epilepsy, and that the sudden deaths in his family suggest cardiovascular disease. A retrospective reading reported in a short article and in press coverage; it is one of several unresolved hypotheses. |
possible | Has the diagnosis of a stroke been overlooked in the symptoms of Julius Caesar? (Galassi FM, Ashrafian H. Neurol Sci 2015;36:1521-2) supports Julius Caesar may have suffered mini-strokes, study finds (AFP report) supports Julius Caesar's Epilepsy: Was It Caused by A Brain Arteriovenous Malformation? (Montemurro N, Benet A, Lawton MT. World Neurosurg 2015;84:1985-7) context |
| R | Other proposed causes include a brain arteriovenous malformation, a brain tumor such as a meningioma, celiac disease, and malaria. Each rests on the same few ancient passages. |
disputed | Julius Caesar's Epilepsy: Was It Caused by A Brain Arteriovenous Malformation? (Montemurro N, Benet A, Lawton MT. World Neurosurg 2015;84:1985-7) supports Was Julius Caesar's epilepsy due to a brain tumor? (Gomez JG, Kotler JA, Long JB. J Fla Med Assoc 1995;82:199-201) supports Julius Caesar (100-44 BC)--did he have a brain tumour? (Retief FP, Cilliers JF. S Afr Med J 2010;100:26-8) context Celiac Disease Could Have Been the Cause of Caesar's Epilepsy (Imparato F. J Clin Gastroenterol 2016;50:797) context Julius Caesar context |
| D | He was assassinated on 15 March 44 BC, the Ides of March, at a meeting of the Senate in Rome, stabbed 23 times; the physician Antistius judged that only the second wound, in the breast, was mortal. Suetonius says he died 'in the fifty-sixth year of his age'. He was 55. The date is in the new Julian calendar. |
confirmed | Suetonius, The Lives of the Caesars: The Life of Julius Caesar (translated by J. C. Rolfe, Loeb Classical Library, 1913) supports Plutarch, Parallel Lives: The Life of Caesar (Loeb Classical Library, volume VII, 1919) supports Julius Caesar supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Recurrent transient episodes of collapse: six days ago a witnessed collapse with stiffening and jerking of both arms for about a minute, a bitten tongue, and about twenty minutes of confusion, after a rising strange feeling and dizziness; two briefer spells of staring and unresponsiveness in the past eighteen months; cause not yet known (seizure, convulsive syncope, or transient ischemic attack) | resolved | confirmed | both_with_link | CLM-0005, CLM-0006, CLM-0007 |
| S | Hypertension, stage 2: 152/94 and 148/92 mmHg today; told of high blood pressure about three years ago and never treated | active | confirmed | active | |
| S | Hyperlipidemia: LDL 158 mg/dL, triglycerides 170 mg/dL, HDL 44 mg/dL | active | confirmed | active | |
| S | Focal epilepsy with a structural vascular cause: focal impaired-awareness seizures with automatisms, one evolving to a bilateral tonic-clonic seizure, arising from a chronic left temporal cortical infarct, with left temporal sharp waves on EEG | active | confirmed | both_with_link | CLM-0005, CLM-0006, CLM-0007, CLM-0013 |
| S | Chronic left posterior temporal cortical infarct, not recognized before the seizures, with moderate small-vessel white matter disease and a non-stenotic left carotid plaque; no residual deficit | active | confirmed | both_with_link | CLM-0014 |
| S | Acute viral upper respiratory infection with low-grade fever and poor sleep, three weeks after starting levetiracetam; rapid COVID-19 and influenza tests negative; resolved | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-08-04 | Hemoglobin [Mass/volume] in Blood | 14.8 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-08-04 | Leukocytes [#/volume] in Blood by Automated count | 6.9 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-08-04 | Platelets [#/volume] in Blood by Automated count | 232 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-08-04 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-08-04 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-08-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-08-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 91 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-08-04 | Glucose [Mass/volume] in Serum or Plasma | 96 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-08-04 | Calcium [Mass/volume] in Serum or Plasma | 9.4 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-08-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-08-04 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-08-04 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 mIU/L Reference 0.4-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-08-04 | Cholesterol [Mass/volume] in Serum or Plasma | 236 mg/dL (high) Reference <=200 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-08-04 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-08-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 158 mg/dL (high) Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-08-04 | Triglyceride [Mass/volume] in Serum or Plasma | 170 mg/dL (high) Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-08-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 2026-08-04 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
| S | 2026-08-18 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-08-18 | Potassium [Moles/volume] in Serum or Plasma | 4.5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-08-18 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-08-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 86 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-09-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-09-15 | Total score [MoCA] | 28 | http://loinc.org · 72172-0 |
| S | 2026-10-27 | Cholesterol [Mass/volume] in Serum or Plasma | 136 mg/dL Reference <=200 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-10-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-10-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 mg/dL Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-10-27 | Triglyceride [Mass/volume] in Serum or Plasma | 110 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-10-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 2026-10-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-10-06 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-08-04 | Body height | 182 cm | 8302-2 | S |
| 2026-08-04 | Body weight | 76 kg | 29463-7 | S |
| 2026-08-04 | Body mass index (BMI) [Ratio] | 22.9 kg/m2 | 39156-5 | S |
| 2026-08-04 | Systolic blood pressure | 152 mm[Hg] | 8480-6 | S |
| 2026-08-04 | Diastolic blood pressure | 94 mm[Hg] | 8462-4 | S |
| 2026-08-04 | Heart rate | 70 /min | 8867-4 | S |
| 2026-08-04 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-04 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-08-18 | Body height | 182 cm | 8302-2 | S |
| 2026-08-18 | Body weight | 75.8 kg | 29463-7 | S |
| 2026-08-18 | Body mass index (BMI) [Ratio] | 22.9 kg/m2 | 39156-5 | S |
| 2026-08-18 | Systolic blood pressure | 140 mm[Hg] | 8480-6 | S |
| 2026-08-18 | Diastolic blood pressure | 88 mm[Hg] | 8462-4 | S |
| 2026-08-18 | Heart rate | 68 /min | 8867-4 | S |
| 2026-08-18 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-18 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-09-08 | Body height | 182 cm | 8302-2 | S |
| 2026-09-08 | Body weight | 75.4 kg | 29463-7 | S |
| 2026-09-08 | Body mass index (BMI) [Ratio] | 22.8 kg/m2 | 39156-5 | S |
| 2026-09-08 | Systolic blood pressure | 136 mm[Hg] | 8480-6 | S |
| 2026-09-08 | Diastolic blood pressure | 86 mm[Hg] | 8462-4 | S |
| 2026-09-08 | Heart rate | 84 /min | 8867-4 | S |
| 2026-09-08 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-09-08 | Body temperature | 37.8 Cel | 8310-5 | S |
| 2026-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-09-15 | Body height | 182 cm | 8302-2 | S |
| 2026-09-15 | Body weight | 75.6 kg | 29463-7 | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 22.8 kg/m2 | 39156-5 | S |
| 2026-09-15 | Systolic blood pressure | 136 mm[Hg] | 8480-6 | S |
| 2026-09-15 | Diastolic blood pressure | 84 mm[Hg] | 8462-4 | S |
| 2026-09-15 | Heart rate | 68 /min | 8867-4 | S |
| 2026-09-15 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-15 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-06 | Body height | 182 cm | 8302-2 | S |
| 2026-10-06 | Body weight | 75.2 kg | 29463-7 | S |
| 2026-10-06 | Body mass index (BMI) [Ratio] | 22.7 kg/m2 | 39156-5 | S |
| 2026-10-06 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-10-06 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-10-06 | Heart rate | 66 /min | 8867-4 | S |
| 2026-10-06 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-06 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-27 | Body height | 182 cm | 8302-2 | S |
| 2026-10-27 | Body weight | 75 kg | 29463-7 | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 22.6 kg/m2 | 39156-5 | S |
| 2026-10-27 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-10-27 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-10-27 | Heart rate | 66 /min | 8867-4 | S |
| 2026-10-27 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-27 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Senior elected official, author, and former army officer; long working days, much public speaking, frequent travel; sleeps about five hours a night in busy weeks
- S Married; lives with his wife; his only child, a daughter, died in childbirth many years ago. He has a household staff and a driver
- S Alcohol: a glass of wine with dinner once or twice a week (AUDIT-C 1); never smoked; no other drug use
- S Rides horses most weekends and walks daily; swims in summer; is usually driven but drives himself at weekends
- S No firearms at home
Functional status
- S Independent in all activities; after the latest spell he was confused for about twenty minutes and tired for the rest of the day, with sore shoulders the next morning
Mental status
- S Alert, articulate, and composed; oriented; full recall of events before and after the spell but none of the spell itself; mood "impatient to get back to work"; PHQ-9 3; no thoughts of self-harm
- S Neurological examination: fluent speech with normal naming and repetition; visual fields full; no pronator drift; normal strength, sensation, reflexes, coordination, and gait; healed bite on the left side of the tongue; no orthostatic drop in blood pressure
Allergies and medications
Allergies
- S No known allergy
Medications
- S Lisinopril 10 mg oral tablet, one tablet by mouth daily
- S Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily
- S Atorvastatin 80 mg oral tablet, one tablet by mouth at bedtime
- S Aspirin 81 mg delayed-release tablet, one tablet by mouth daily
- S Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours as needed for fever or sore throat (no more than 3 g a day)
- S Amlodipine 5 mg oral tablet, one tablet by mouth daily
Procedures and immunizations
Procedures
- S 12-lead ECG: sinus rhythm at 70 per minute, PR 168 ms, QRS 92 ms, QTc 412 ms, voltage criteria for left ventricular hypertrophy; no pre-excitation, Brugada pattern, or heart block
- S 14-day ambulatory ECG patch, fitted the day after the first visit: sinus rhythm throughout, no atrial fibrillation or flutter, no pause longer than 2 seconds, no high-grade block; one patient-triggered event (light-headed on standing) in sinus rhythm
- S Routine EEG with sleep: intermittent left temporal sharp waves in drowsiness and light sleep; normal background; no seizure recorded
- S MRI of the brain with diffusion-weighted, susceptibility-weighted, and epilepsy-protocol sequences: no acute infarct; a chronic 1.5 cm cortical and subcortical infarct with gliosis in the left posterior temporal lobe; moderate periventricular and deep white matter hyperintensities (Fazekas grade 2); no microbleeds, mass, vascular malformation, cyst, or calcified lesion; hippocampi normal
- S CT angiography of the head and neck: calcified plaque at the left carotid bifurcation with less than 30 percent stenosis; no other extracranial or intracranial stenosis, dissection, aneurysm, or arteriovenous malformation
- S Transthoracic echocardiogram with agitated saline: ejection fraction 60 percent, mild concentric left ventricular hypertrophy, normal left atrial size, no thrombus or valve disease; no shunt
- S Second ambulatory ECG monitor for four more weeks (more than 40 days of monitoring in all): sinus rhythm throughout; no atrial fibrillation or flutter; rare isolated ectopic beats
- S Home sleep apnea test: apnea-hypopnea index 4 per hour, oxygen saturation nadir 91 percent; no sleep apnea
- S Advance care planning conversation, about 20 minutes
Immunizations
- S 2019-04-10: Tetanus, diphtheria, and pertussis (Tdap) booster
- S 2026-10-06: Influenza vaccine, 2026-2027 season
- S 2026-10-06: Recombinant zoster vaccine, dose 1 of 2
- S 2026-10-06: Pneumococcal conjugate vaccine (PCV20), single dose
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D about 82 to 81 BC: A severe quartan fever (a fever every fourth day) while in hiding as a young man (CLM-0004)
- D date not recorded: Plutarch: 'distemper in the head' and 'epileptic fits', the first at Corduba in Spain; the date is not recorded (CLM-0005)
- D his last years; no dates recorded: Suetonius: sudden fainting fits and nightmares towards the end of his life, and two attacks of the 'falling sickness' (comitialis morbus) on campaign (CLM-0006)
- D 6 April 46 BC in the old Roman calendar (about 7 February 46 BC, Julian): By one account in Plutarch, his 'usual sickness' seized him at the battle of Thapsus and he was carried to a tower (CLM-0007)
- R retrospective interpretation: The nature of the attacks is disputed: epilepsy, transient ischemic attacks, and other causes have all been proposed (CLM-0013, CLM-0014, CLM-0015)
Family history
- D father: Died suddenly in the morning, without apparent cause, while putting on his shoes, when his son was fifteen; cause not recorded in the cited source
- D natural daughter: Died in childbirth as a young woman
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Cause of the spells established and explained to him by the neurology visit | 2026-08-18 | completed | Focal epilepsy with a structural vascular cause, from a chronic left temporal cortical infarct; syncope and transient ischemic attack judged unlikely |
| No seizures on levetiracetam through the ten-week review | 2026-10-27 | completed | No seizure or spell since levetiracetam was started ten weeks ago |
| Office blood pressure below 130/80 mmHg | 2026-10-27 | completed | 124/76 mmHg on lisinopril 10 mg and amlodipine 5 mg |
| LDL cholesterol below 70 mg/dL on a high-intensity statin | 2026-10-27 | completed | LDL 68 mg/dL after ten weeks of atorvastatin 80 mg |
| No driving, swimming alone, or riding alone while the seizure-free period is counted, with a written seizure action plan for his staff | 2026-10-27 | active | Not driving; a driver and a riding companion arranged; seizure action plan given to his staff |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Work-up of transient loss of consciousness: witness account, orthostatic vital signs, 12-lead ECG today, a 14-day ambulatory ECG patch from tomorrow, blood count, electrolytes, calcium, glucose, kidney and liver tests, HbA1c, lipids, and TSH; EEG and MRI of the brain with diffusion-weighted and epilepsy-protocol sequences; CT angiography of the head and neck; transthoracic echocardiogram | completed | GL-AAN-FIRSTSZ-2015, GL-ACC-SYNC-2017, GL-AHA-SSP-2021 |
| Neurology consultation: is this epilepsy, syncope, or transient ischemic attack; review of the EEG, MRI, and vascular imaging; whether to start an antiseizure medicine and which; stroke prevention; and driving | completed | GL-AAN-FIRSTSZ-2015, GL-ILAE-SZ-2017 |
| Seizure safety from today: no driving until a seizure-free period set by state law and his neurologist; showers rather than baths; no swimming or riding alone; no climbing to heights; regular sleep of at least seven hours; a written seizure action plan for his staff, including when to call emergency services | completed | GL-AAN-FIRSTSZ-2015 |
| Blood pressure: lisinopril 10 mg daily from today; home blood pressure log twice daily; potassium and creatinine in two weeks; target below 130/80 mmHg | completed | GL-AHA-HTN-2025, GL-CMID-2026 |
| Antiseizure medicine: levetiracetam 500 mg twice daily, with teaching about irritability, low mood, and drowsiness; a seizure diary; no missed doses | completed | GL-AAN-NEWASM-2018, GL-AAN-FIRSTSZ-2015 |
| Secondary stroke prevention for the cortical infarct: aspirin 81 mg daily, atorvastatin 80 mg at bedtime with a lipid panel at 4 to 12 weeks (LDL target below 70 mg/dL), blood pressure below 130/80 mmHg with a second drug if needed, a home sleep apnea test, and a further four weeks of ambulatory rhythm monitoring (more than 30 days in all) for occult atrial fibrillation | completed | GL-AHA-SSP-2021, GL-AHA-SILENT-2017, GL-CMID-2026 |
| Lifestyle: Mediterranean-style diet with sodium below 2.3 g a day; aerobic activity at least 150 minutes a week; alcohol kept at his present low level; no tobacco | completed | GL-AHA-SSP-2021, GL-CMID-2026 |
| Mood and cognition after the diagnosis: PHQ-9 four weeks after starting levetiracetam and then periodically; MoCA in the first months after the infarct was found | completed | GL-CMID-2026, GL-AHA-SSP-2021 |
| Adult prevention plan: influenza, pneumococcal, and recombinant zoster vaccines; hepatitis C, hepatitis B, and HIV screening; colonoscopy for colorectal cancer screening; eye examination; PSA discussion at 55 | completed | GL-PREV-2026, GL-USPSTF-AB, GL-CDC-ADULT-2026, GL-USPSTF-CRC-2021 |
Planned encounters
- 2026-08-04 — Urgent visit after a witnessed collapse with jerking and confusion, the third spell in eighteen months: history, examination, ECG, tests, cardiac monitor, seizure safety, and neurology referral (ENC-001)
- 2026-08-18 — Two-week follow-up with the neurology consultation: EEG, MRI, vascular imaging, echocardiogram, and monitor reviewed; diagnosis made and treatment started (ENC-002)
- 2026-09-08 — Same-day sick visit for a cold with low fever (ENC-005, unscheduled)
- 2026-09-15 — Four-week review of levetiracetam, blood pressure, the second rhythm monitor, mood, and cognition (ENC-003)
- 2026-10-06 — Adult preventive visit (ENC-006)
- 2026-10-27 — Ten-week review: seizure control, lipids on atorvastatin, blood pressure, and driving and safety (ENC-004)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Sick Visit
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Preventive Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Neurology referral
- Neurology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Sick Visit (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Preventive Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Neurology referral (XML)
- Neurology consultation (XML)
Sources
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the seizure-versus-syncope-versus-TIA reasoning, the classification as focal epilepsy with a structural vascular cause, the choice of levetiracetam, the decision to treat the covert infarct with secondary rather than primary prevention, the 30-day monitor, the blood pressure plan, and the driving advice. |
| provenance review | not_started | Suetonius and Plutarch in the Loeb translations on LacusCurtius, the Latin text of Suetonius, Pliny's Natural History on Perseus, the Loeb introduction to the Spanish War, three encyclopedia articles, PubMed records of seven retrospective articles, and a news report of Galassi and Ashrafian logged. The ancient reports of falling attacks, fainting, and nightmares are D; every modern diagnosis (epilepsy, transient ischemic attacks, malformation, tumor, celiac disease, neurocysticercosis) is R. |
| safe messaging review | not_started | His assassination is recorded once in the timeline and in one claim, without detail beyond the ancient report, and is not foreshadowed in the modern episode. No statement, decision, or health fact is attributed to his wife or any other real person. PHQ-9 scores are below 10 with item 9 scored 0, so no safety assessment is required. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.